B
Bull
Bull · 25%NLSP
$2.96
シナリオ価格
$7.620
+0.226 (+2.97%)終値時点
Loading chart…
- High
- 8.300
- Open
- 7.701
- VWAP
- 7.84
- Vol
- 4.76M
- Mkt Cap
- 10.41M
- Low
- 7.600
- Amount
- 37.34M
- EV/EBITDA, TTM
- 0.00
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
バリュエーション指標
The current forward P/E ratio for NLS Pharmaceutics AG (NLSP) is -0.09, compared to its 5-year average forward P/E of -2.97.
Alphio AI Price Scenarios for NLSP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NLSP
イベントタイムライン
ニュース
3.510-30PRnewswireNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
8.510-29NewsfilterNLS Pharmaceutics and Kadimastem Confirm Fulfillment of Key Conditions for Merger and Set Delisting Date for Kadimastem Shares
8.510-29PRnewswireNLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
8.510-27PRnewswireNLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
8.510-23PRnewswireNLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
NLSP FAQ — answered by Alphio AI
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。